The COVID-19 pandemic is a health-care crisis. It has, in many ways, focused a lens on the importance of the life sciences, technology development, and innovation strategy on the health and economic well-being of all Canadians. Yet, we all ache for the COVID context to be finally removed from all our decision-making: how we work, who we visit, how we interact, where we go … for example. The same applies to our thinking on Canada’s bio-manufacturing strategy. It is time to transition from defence to offence and focus on a strategy that will create Canadian advantages in the future around Canadian strengths in the life sciences.
Enter your email address to
register a free account.